Kamal Imaging And Pathology Centre Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 27-12-2024
- Paid Up Capital ₹ 0.10 M
as on 27-12-2024
- Company Age 13 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.21 Cr
as on 27-12-2024
- Revenue -2.49%
(FY 2022)
- Profit -87.75%
(FY 2022)
- Ebitda -11.70%
(FY 2022)
- Net Worth -63.43%
(FY 2022)
- Total Assets -5.78%
(FY 2022)
About Kamal Imaging And Pathology Centre
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.21 Cr.
Kamal Agarwal, Mamta Agarwal, and Nirmal Mundra serve as directors at the Company.
- CIN/LLPIN
U85110RJ2011PTC037240
- Company No.
037240
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Dec 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kamal Imaging And Pathology Centre?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamal Agarwal  | Director | 05-Dec-2011 | Current |
| Mamta Agarwal | Director | 05-Dec-2011 | Current |
| Nirmal Mundra | Director | 27-Mar-2012 | Current |
Financial Performance of Kamal Imaging And Pathology Centre.
Kamal Imaging And Pathology Centre Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 2.49% decrease. The company also saw a substantial fall in profitability, with a 87.75% decrease in profit. The company's net worth observed a substantial decline by a decrease of 63.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kamal Imaging And Pathology Centre?
In 2020, Kamal Imaging And Pathology Centre had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Siemens Financial Services Private Limited Creation Date: 21 Jun 2013 | ₹2.64 Cr | Open |
India Infoline Finance Limited Creation Date: 18 Jul 2012 | ₹5.68 M | Open |
How Many Employees Work at Kamal Imaging And Pathology Centre?
Unlock and access historical data on people associated with Kamal Imaging And Pathology Centre, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kamal Imaging And Pathology Centre, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kamal Imaging And Pathology Centre's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
